
Post
ARRIWYKS
#ModernaQ3VaccineSales
Why YES:
mNEXSPIKE COVID + mFLUSIVA flu (1st mRNA flu FDA 50+) approved. Cancer vax Intismeran (MRK) Phase 3 hit. FY +10% rev guide. Cash $8B+ after $950M litigation.
Valuation insane:
$200 vs $22 low → +580% YTD, +295% 6M, high $254. P/S 41x, P/B 9x, EPS -$7.25, Net -141% margin. Street PT $118 (42% down). 3 Buy/14 Hold/3 Sell. Oct 22 -25% on cancer data leak.
Call: 80% EPS BEAT (season + cost cuts) but stock - Sell the beat — needs >$950M + loss <-$0.90 + 2026 raise

Disclaimer: OKX Orbit content is provided for informational purposes only. Learn more
Replies
No comments yet. Be the first to reply!
Trending crypto
BTC/USDTBitcoin
$61,692-0.02%
ETH/USDTEthereum
$1,735.02-0.03%
SOL/USDTSolana
$72.09-0.02%
Today’s market buzz
1#Anthropic launches IPO roadshow, valuation rebounds to $1.8 trillion
Hot


2#Federal Reserve officials warn that AI investment is driving up inflation, and rate hike options are not ruled out
Hot

3#Twenty One Capital increased its holdings by 154 BTC, marking the first time since July 2025

